NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
NewAmsterdam Pharma Stock Performance
Shares of NewAmsterdam Pharma stock opened at $21.76 on Friday. The firm has a market cap of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. The business's 50 day simple moving average is $21.66 and its 200 day simple moving average is $21.20. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.
Analysts Set New Price Targets
Several brokerages recently commented on NAMS. Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Needham & Company LLC reduced their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $43.33.
View Our Latest Research Report on NewAmsterdam Pharma
Institutional Trading of NewAmsterdam Pharma
A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $50,000. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the fourth quarter worth $80,000. Quarry LP lifted its stake in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after acquiring an additional 6,247 shares during the last quarter. Finally, Barclays PLC grew its position in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
